Article Per Year (5 Year)
p-Index From 2020 - 2025
0
P-Index
This Author published in this journals
All Journal INDONESIAN JOURNAL OF PHARMACY Jurnal Farmasi
Zulies Ikawati, Zulies
Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia.
Dentistry Health Professions Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Effects of pH, temperature and storage on the stability of MJ-30 protein isolated from Mirabilis jalapa L leaves ., Sudjadi; Ikawati, Zulies; ., Sismindari; Rahayu, Putu Riana Suastari
INDONESIAN JOURNAL OF PHARMACY Vol 15 No 1, 2004
Publisher : Faculty of Pharmacy Universitas Gadjah Mada, Yogyakarta, Skip Utara, 55281, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (358.748 KB) | DOI: 10.14499/indonesianjpharm0iss0pp1-6

Abstract

The total protein of Mirabilis jalapa L leaves had the ability to cleave supercoiled DNA and showed toxicity on HeLa and Raji cell-lines. The 30 kD protein (MJ-30) purified by cationic exchange chromatography possessed activites as RIP e.g DNA supercoiled cleavage and RNA N-glycosidase activity. The aim of this study was to prepare pure MJ-30 and to observe the stability of MJ-30 .MJ-30 of M.jalapa L leaves was purified using the combination of ammonium sulphate fractionation and cationic exchange chromatography with NaCl gradient elution. MJ-30 was subjected for its stability to assays against pH, temperature, and storage period.Stability assay showed that MJ-30 is stabil at pH 5-6, then the activity decreased as the pH increased. This protein was stable at 300 – 550C, and the activity decreased when the temperature increased. Storage at 40C, MJ-30 was stable until 12 days but the activity was decreasing. However, at 300C, MJ-30 was stable for 3 days only. Glycerol addition to the MJ-30 solution has made the activity stable for 18 days at 40C and 300C storage.Keyword : Protein MJ-30, Leaves of Mirabilis jalapa L, stability, pH, temperature, storage
Perbandingan Efektivitas Produk Filgrastim pada Pasien Keganasan Limfoma yang Menerima Kemoterapi di RSUP dr. Sardjito Yogyakarta Setiani, Dhien; Ikawati, Zulies; Widayati, Kartika
Jurnal Farmasi (Journal of Pharmacy) Vol. 4 No. 1 (2015): Jurnal Farmasi (Journal of Pharmacy), October 2015
Publisher : Jurnal Farmasi (Journal of Pharmacy)

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Neutropenia is a common toxicity in cancer patients receiving chemotherapy myelotoxic as lymphoma result. Granulocyte Colony Stimulating Factor (G-CSF) is clinically recommended for neutropenia. Filgrastim is a generic name of the brand G - CSF products circulating in Indonesia such as Filgrastim brand A and brand B produced by a different manufacturer. The differences Filgrastim brand A and brand B produced by non-factory is that Filgrastim A product’s price is cheaper than brand B. Comparison of the effectiveness of Filgrastim brand A and brand B in patients at DR.Sardjito Hospital Yogyakarta need to be examined to evaluate the effectiveness of the type of drugs has been clinically used. The purpose of this study was to compare the effectiveness of Filgrastim A and B on the use of daily clinical practice at RSUP Dr. Sardjito Yogyakarta. The design of this study is analytic retrospective cohort study that is applied for patients receiving chemotherapy in cancer Installation Tulip Hospital Dr. Sardjito. Data was retrieved from medical records the period January 2013 to March 2015. Comparison of the effectiveness of filgrastim uses the parameter of time to reach the Absolute Neutrophil Count (ANC) recovery. Data of characteristics subjects were analyzed by using chi square Goodness of Fit for categorical data and independent t test for numerical data. The comparison of effectiveness of filgrastim was analyzed by using survival analysis. A total of the study showed that there were 80 subjects which consists of 192 episodes of neutropenia incidence of filgrastim therapy. From 80 subjects, there were 43 subjects ( 53,5 % ) which consist of 72 episodes of neutropenic (33 episodes with filgrastim brand A and 39 episodes with filgrastim brand B) that met the inclusion criteria. The result of the comparison of filgrastim effectiveness based on time to ANC recovery, according to the bivariate Kaplan-Meier with the laboratory observation data 24 hours post last injections, it shows that Filgrastim brand A has a median recovery time faster than Filgrastim brand B (1,00 vs 2,00 p< 0,05). The conclusions of this study , in the ANC recovery time, Filgrastim brand A more effective than Filgrastim brand B.
Co-Authors Kartika Widayati Taroeno Hariadi Putu Riana Suastari Rahayu, Putu Riana Suastari Setiani, Dhien Sismindari . Sudjadi ., Sudjadi